glaucoma
Conditions
Interventions
Benzalkonium chloride (BAK)-preserved latanoprost ophthalmic solution 0.005% once daily for 3 months into one of a subject
Benzalkonium chloride (BAK)-free travoprost ophthalmic solution 0.004% once d
Sponsors
Department of Ophtalmology, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.adult patients with OAG or glaucoma suspects treated latanoprost monotherapy for at least 3 months 2.at baseline, fluorescent staining score of superior punctate keratitis was over 1 in both eyes through consecutive 2 visits 3.out of consideration of IOP under the treatment
Exclusion criteria
Exclusion criteria: 1) a past history of ocular inflammatory diseases, ocular surgery, or traumatic diseases less than 3 months before entry, 2) use of other topical eye drops or systemic ocular hypertensive drugs, 3) patients who wear contact lenses, or 4) under 20 years old during the study. Moreover, patients at risk of visual field progression or visual acuity worsening during the study were excluded according to the judgement of physicians in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of superior punctate keratitis (SPK) | — |
Secondary
| Measure | Time frame |
|---|---|
| the change of tear break up time and IOP reduction | — |
Countries
Japan
Contacts
Public Contactmakoto aihara
University of Tokyo Department of Ophthalmology
Outcome results
None listed